glp-1 and alcohol consumption A preliminary study of the physiological perceptual effects of receptor agonists during in people with obesity GLP-1 RAs may reduce alcohol-related

CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans Posted on April 5, 2024 CMS Issued Coverage Guidance on GLP-1 Anti-Obesity Drugs Requiring Considerations for Health Plans GLP-1s (glucagon-like peptide 1 agonist) came up in the news again after the Centers for Medicare and Medicaid Services (CMS) issued coverage guidance on GLP-1 anti-obesity drugs with expanded indications on March 20, 2024.* Since the inception of Medicare Part D, drugs used for weight loss have been excluded from basic coverage

Characterization of Brainstem Preproglucagon Projections to the Paraventricular and Dorsomedial Hypothalamic Nuclei

Who Typically Looks Into CJC-1295 Individuals researching CJC 1295 are often looking to: Improve body composition and reduce fat mass Recover faster from training or injury Restore vitality and sleep quality associated with age related GH decline Support joint, tendon, and skin health Although CJC 1295 may seem appealing for these goals, the peptides research status and lack of FDA approval for general use make it unsuitable for self administration

So when one of our physicians or nurse practitioners sees a patient with obesity and we are prescribing, deprescribing, managing side effects or addressing abnormal laboratory values, we work with the PCP, we communicate with the PCP to try to create a coordinated approach so that the patient is getting excellent primary care to address the multitude of clinical conditions that they may have, while also receiving excellent specialty care to manage this underlying complicated disease state